AAM Offers Drug Manufacturing Repatriation Plan … For A Price
Executive Summary
Under generic industry group’s proposal, the federal government would have to pay more for drugs to ensure industry investments in domestic manufacturing pay off.
You may also be interested in...
New AAM CEO: Traditional Lobbying On Lowering Health Care Costs Can Mix With COVID-19 Talks
Dan Leonard is working on post-pandemic generic drug issues, using coronavirus as a way to get in front of lawmakers.
Can 'Buy American’ Executive Order Shake Up ‘Dickensian’ Manufacturing Dynamics?
Order sets a path for federal government to use its power as a purchaser of pharmaceuticals to nurture a high-tech domestic pharma manufacturing sector that would increase resilience against threats that could isolate the US from countries like China that are important nodes in the global manufacturing supply chain.
Can 'Buy American’ Executive Order Shake Up ‘Dickensian’ Manufacturing Dynamics?
The Trump administration’s move to strengthen domestic manufacture of essential medicines raises a lot of questions – and industry’s ire.